Cargando…

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma

Antibody drug conjugates (ADCs) can deliver potent drugs to cancer cells by employing the specificity of monoclonal antibodies (mAbs). ADCs have demonstrated significant anticancer activity and, in 2011, brentuximab vedotin has been approved by the FDA for the treatment of Hodgkin's and anaplas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Jason, O’Donnell, Robert T., Abuhay, Mastewal, Tuscano, Joseph M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525602/ https://www.ncbi.nlm.nih.gov/pubmed/23264893 http://dx.doi.org/10.4161/onci.21815

Ejemplares similares

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
por: Tuscano, Joseph M., et al.
Publicado: (2011)

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts
por: O’Donnell, Robert T., et al.
Publicado: (2009)

Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells
por: Polito, Letizia, et al.
Publicado: (2017)

Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
por: Tazzari, P. L., et al.
Publicado: (1993)

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation
por: Barisone, Gustavo A., et al.
Publicado: (2018)

Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities
por: Leitman, Ellen M., et al.
Publicado: (2017)

Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells
por: Quadros, Edward V., et al.
Publicado: (2013)

Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy
por: Polito, Letizia, et al.
Publicado: (2011)

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
por: Martin, Shiloh M, et al.
Publicado: (2011)

Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
por: Flavell, D. J., et al.
Publicado: (1995)

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009)

The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells
por: Wensley, Harrison J., et al.
Publicado: (2021)

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
por: Li, Xiaofan, et al.
Publicado: (2023)

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
por: Wu, Chi-Heng, et al.
Publicado: (2022)

Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency
por: Castiello, Maria Carmina, et al.
Publicado: (2020)

A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo
por: Levis, Daniel J., et al.
Publicado: (2023)

Analysis of the Sequence Preference of Saporin by Deep Sequencing
por: Hauf, Samuel, et al.
Publicado: (2022)

A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer
por: Zuppone, Stefania, et al.
Publicado: (2022)

Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma
por: Daniels-Wells, Tracy R., et al.
Publicado: (2023)

Saporin-S6: A Useful Tool in Cancer Therapy
por: Polito, Letizia, et al.
Publicado: (2013)

Streptavidin-Saporin: Converting Biotinylated Materials into Targeted Toxins
por: Ancheta, Leonardo R., et al.
Publicado: (2023)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
por: Hicks, Stuart W., et al.
Publicado: (2017)

Targeted Destruction of Photosensitive Retinal Ganglion Cells with a Saporin Conjugate Alters the Effects of Light on Mouse Circadian Rhythms
por: Göz, Didem, et al.
Publicado: (2008)

Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma
por: Eberth, Sonja, et al.
Publicado: (2010)

Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
por: Flavell, D. J., et al.
Publicado: (1992)

Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins
por: Giansanti, Francesco, et al.
Publicado: (2018)

New Insights on Saporin Resistance to Chemical Derivatization with Heterobifunctional Reagents
por: Bortolotti, Massimo, et al.
Publicado: (2023)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin
Publicado: (1987)

Thermo-stability and antitumor activity on colon cancer cell lines of monoclonal anti-CEA antibody-saporin immunotoxin.
por: Manosroi, J., et al.
Publicado: (1992)

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma
por: Ansell, Stephen M.
Publicado: (2017)

Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
por: Flavell, D. J., et al.
Publicado: (1991)

Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents
por: Smith, Wendy S., et al.
Publicado: (2019)

Bleomycin in Hodgkin's Lymphoma – A Boon or a Bane? – A Retrospective Study of Bleomycin Pulmonary Toxicity in Hodgkin's Lymphoma
por: Udupa, Chethana Babu K, et al.
Publicado: (2019)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Pulmonary toxicity induced by bleomycin in a patient with Hodgkin lymphoma
por: Oliveira, CF, et al.
Publicado: (2005)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Pei, Fajun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v4ologcn5dbrp1drkvrpq3mvji